Severe hepatic dysfunction is associated with venous thromboembolic events in phase 1 clinical trials

Por Mansfield, A.S., Tafur, A.J., Vulih, D., Smith, G.L., Harris, P.J., Ivy, S.P.
Publicado no Thromb Res (2015)

The Role of Age on Dose Limiting Toxicities (DLTs) in Phase I Dose-escalation Trials

Por Schwandt, A, Harris, P. J., Hunsberger, S., Deleporte, A., Smith, G. L., Vulih, D., Anderson, B. D., Ivy, S. P.
Publicado no Clin Cancer Res (2014)

Carcinogen-induced mdr overexpression is associated with xenobiotic resistance in rat preneoplastic liver nodules and hepatocellular carcinomas.

Por Fairchild, C R, Ivy, S P, Rushmore, T, Lee, G, Koo, P, Goldsmith, M E, Myers, C E, Farber, E, Cowan, K H
Publicado em 1987

A phase 1/PK study of Sunitinib with highly active antiretroviral therapy (HAART) in HIV+ patients with solid tumors: AIDS malignancy consortium study 061

Por Deeken, John F, Rudek, Michelle A, Moore, Page C, Aboulafia, David, Sullivan, Ryan, Gerecitano, John, Cianfrocca, Mary, Henry, David, Ratner, Lee, Dezube, Bruce, Mosby, Kimberly, Tibbals, Melinda, Little, Richard F, Ivy, S P, Mitsuyasu, Ronald T
Publicado em 2012

Phase I study of pegylated liposomal doxorubicin and the multidrug-resistance modulator, valspodar

Por Fracasso, P M, Blum, K A, Ma, M K, Tan, B R, Wright, L P, Goodner, S A, Fears, C L, Hou, W, Arquette, M A, Picus, J, Denes, A, Mortimer, J E, Ratner, L, Ivy, S P, McLeod, H L
Publicado em 2005

A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503)

Por Sahebjam, S, Bedard, P L, Castonguay, V, Chen, Z, Reedijk, M, Liu, G, Cohen, B, Zhang, W-J, Clarke, B, Zhang, T, Kamel-Reid, S, Chen, H, Ivy, S P, Razak, A R A, Oza, A M, Chen, E X, Hirte, H W, McGarrity, A, Wang, L, Siu, L L, Hotte, S J
Publicado em 2013